IL163780A0 - Crystalline parecoxib sodium - Google Patents

Crystalline parecoxib sodium

Info

Publication number
IL163780A0
IL163780A0 IL16378003A IL16378003A IL163780A0 IL 163780 A0 IL163780 A0 IL 163780A0 IL 16378003 A IL16378003 A IL 16378003A IL 16378003 A IL16378003 A IL 16378003A IL 163780 A0 IL163780 A0 IL 163780A0
Authority
IL
Israel
Prior art keywords
parecoxib sodium
crystalline
crystalline parecoxib
sodium
parecoxib
Prior art date
Application number
IL16378003A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL163780A0 publication Critical patent/IL163780A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
IL16378003A 2002-03-15 2003-03-12 Crystalline parecoxib sodium IL163780A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36456702P 2002-03-15 2002-03-15
US41798702P 2002-10-11 2002-10-11
PCT/US2003/007484 WO2003078408A1 (en) 2002-03-15 2003-03-12 Crystalline parecoxib sodium

Publications (1)

Publication Number Publication Date
IL163780A0 true IL163780A0 (en) 2005-12-18

Family

ID=28045416

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16378003A IL163780A0 (en) 2002-03-15 2003-03-12 Crystalline parecoxib sodium

Country Status (18)

Country Link
US (1) US20030232871A1 (xx)
EP (1) EP1485362A1 (xx)
JP (1) JP2005529084A (xx)
KR (1) KR100763045B1 (xx)
CN (1) CN1642926A (xx)
AR (1) AR038985A1 (xx)
AU (1) AU2003220180A1 (xx)
BR (1) BR0308431A (xx)
CA (1) CA2478500A1 (xx)
CO (1) CO5631437A2 (xx)
IL (1) IL163780A0 (xx)
MX (1) MXPA04008932A (xx)
MY (1) MY148518A (xx)
NZ (1) NZ535951A (xx)
PL (1) PL372880A1 (xx)
RU (1) RU2300529C2 (xx)
TW (1) TW200400949A (xx)
WO (1) WO2003078408A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143431A1 (en) * 2003-04-04 2005-06-30 Hetero Drugs Limited Novel crystalline forms of parecoxib sodium
JP2007507538A (ja) 2003-10-02 2007-03-29 エラン ファーマシューティカルズ，インコーポレイテッド 疼痛軽減方法
EP1708700A1 (en) * 2003-12-24 2006-10-11 Pharmacia Corporation Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
US7796785B2 (en) * 2005-03-03 2010-09-14 Fujifilm Corporation Image extracting apparatus, image extracting method, and image extracting program
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN106692079A (zh) * 2016-12-26 2017-05-24 上药东英（江苏）药业有限公司 一种帕瑞昔布钠长效冻干粉针制剂
CN106580893A (zh) * 2016-12-26 2017-04-26 上药东英（江苏）药业有限公司 一种帕瑞昔布钠冻干粉针制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2249009C (en) * 1996-04-12 2003-09-16 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US7695736B2 (en) * 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
IL161086A0 (en) * 2001-10-02 2004-08-31 Pharmacia Corp Method for preparing benzenesulfonyl compounds

Also Published As

Publication number Publication date
NZ535951A (en) 2006-02-24
MY148518A (en) 2013-04-30
AU2003220180A1 (en) 2003-09-29
US20030232871A1 (en) 2003-12-18
CO5631437A2 (es) 2006-04-28
EP1485362A1 (en) 2004-12-15
AR038985A1 (es) 2005-02-02
CA2478500A1 (en) 2003-09-25
JP2005529084A (ja) 2005-09-29
KR100763045B1 (ko) 2007-10-04
PL372880A1 (en) 2005-08-08
CN1642926A (zh) 2005-07-20
WO2003078408A1 (en) 2003-09-25
MXPA04008932A (es) 2004-11-26
RU2004127585A (ru) 2005-04-10
BR0308431A (pt) 2005-01-18
KR20040095288A (ko) 2004-11-12
RU2300529C2 (ru) 2007-06-10
TW200400949A (en) 2004-01-16

Similar Documents

Publication Publication Date Title
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
HK1077068A1 (en) Azolidinone-vinyl fused-benzene derivatives
IL166121A0 (en) Indole-3-sulphur derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
PL376475A1 (en) N-substituted-2-oxodihydropyridine derivatives
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
ZA200500471B (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
GB2392460B (en) Delayed-gelation solution
AU2003268304A8 (en) Toolholder
IL163780A0 (en) Crystalline parecoxib sodium
IL165572A0 (en) 1-Ä(indoÜ-3-yl)carbonylÜpiperazine derivatives
AU2003297594A8 (en) Crystalline form
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
GB0211181D0 (en) Toothbrush (liquibrush)
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0213488D0 (en) 2-Naphthamide derivatives
NO20044302L (no) Krystallinsk parecoxibnatrium
AU2003238669A1 (en) Novel crystalline forms of parecoxib sodium
AU2003243397A8 (en) Homo-camptothecin derivatives
GB0228533D0 (en) Crystalline form
IL169772A0 (en) Crystalline modification
AU2003285777A8 (en) 3-substituted-4-pyrimidone derivatives
GB0221143D0 (en) Dihydropyridinone derivatives
GB0210512D0 (en) Tetrahydro-napthalene derivatives